Extravascular ICD OK’d; Win for Million Hearts; SGLT2i Struggles at EF>60%

Medtronic announced that the FDA approved the Aurora extravascular implantable cardioverter-defibrillator for the treatment of tachycardia and prevention of sudden cardiac arrest.

The Million Hearts Model, which gave clinics and hospitals financial incentives to assess and reduce cardiovascular disease, reduced heart attacks and strokes in a cluster-randomized trial. (JAMA)

Echocardiographic measurements of the proximal ascending aorta were helpful for early differentiation between type A acute aortic dissection and ST-elevation myocardial infarction. (Journal of the American Heart Association)

An individual patient-level meta-analysis of the TWILIGHT and TICO trials supported the concept of monotherapy with a P2Y12 inhibitor after a short period of dual antiplatelet therapy in acute coronary syndrome. (Circulation)

Low-risk patients had a 93% survival rate 5 years after surgical aortic valve replacement in a national cohort study. (Annals of Thoracic Surgery)

Anemic patients with severe aortic stenosis often had gastrointestinal angiodysplasia, which was reduced after transcatheter aortic valve replacement, a prospective study showed. (New England Journal of Medicine)

Study suggests little value of systemic family genetic screening for relatives of genotype-negative index patients with hypertrophic cardiomyopathy. (Journal of the American College of Cardiology)

The SGLT2 inhibitor ertugliflozin (Steglatro) did not show that its ability to reduce heart failure hospitalizations applied to people with baseline ejection fractions above 60%. (European Heart Journal)

Catheter-directed thrombolysis carried a relative survival advantage compared with anticoagulation alone or systemic thrombolysis in a meta-analysis. (JACC: Cardiovascular Interventions)

ECGs in sinus rhythm were mined by a deep learning model for signs of atrial fibrillation. (JAMA Cardiology)

The benefit of remote ischemic conditioning for stroke patients seemed to hinge on whether they had large artery atherosclerosis. (Stroke)

Children with familial hypercholesterolemia continued to show no cognitive harms from evolocumab (Repatha) treatment in the 80-week open-label extension study of HAUSER-RCT. (European Journal of Preventive Cardiology)

Later-life cognition in women was tied to mid-life adherence to the Dietary Approaches to Stop Hypertension diet. (Alzheimer’s & Dementia)

Please enable JavaScript to view the

comments powered by Disqus.